Matthew Sykes
Stock Analyst at Goldman Sachs
(3.77)
# 753
Out of 4,983 analysts
205
Total ratings
50.7%
Success rate
8.04%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $10.06 | -50.30% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $3.91 | -23.27% | 9 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $13.13 | -50.50% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $33.26 | +35.30% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $7.50 | +6.67% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $27.08 | +77.25% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $16.30 | +4.29% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $173.13 | -7.58% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $7.99 | +25.16% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $85.28 | +46.58% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $12.71 | +10.15% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $190.47 | +26.00% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $14.18 | +83.36% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $151.60 | +12.14% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $55.40 | +1.08% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $121.37 | -34.09% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.23 | +21.95% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $175.01 | +8.57% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $0.75 | +133.24% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $2.89 | +47.06% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $32.28 | +14.62% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $52.94 | +22.78% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $186.81 | +33.83% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.28 | +354.55% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,276.10 | +1.87% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $10.63 | +12.89% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $480.74 | +33.13% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $127.19 | +14.00% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $45.60 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $10.06
Upside: -50.30%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $3.91
Upside: -23.27%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $13.13
Upside: -50.50%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $33.26
Upside: +35.30%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $7.50
Upside: +6.67%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $27.08
Upside: +77.25%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $16.30
Upside: +4.29%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $173.13
Upside: -7.58%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $7.99
Upside: +25.16%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $85.28
Upside: +46.58%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $12.71
Upside: +10.15%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $190.47
Upside: +26.00%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $14.18
Upside: +83.36%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $151.60
Upside: +12.14%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $55.40
Upside: +1.08%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $121.37
Upside: -34.09%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.23
Upside: +21.95%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $175.01
Upside: +8.57%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $0.75
Upside: +133.24%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $2.89
Upside: +47.06%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $32.28
Upside: +14.62%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $52.94
Upside: +22.78%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $186.81
Upside: +33.83%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.28
Upside: +354.55%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,276.10
Upside: +1.87%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $10.63
Upside: +12.89%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $480.74
Upside: +33.13%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $127.19
Upside: +14.00%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $45.60
Upside: -